2015 Fiscal Year Final Research Report
Identifing novel therapeutic target molecules in multiple myeloma using BCL9-ChIPSeq
| Project/Area Number |
25461430
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAMIHARA YUSUKE 札幌医科大学, 医学部, 研究員 (10624421)
KATO JUNJI 札幌医科大学, 医学部, 教授 (20244345)
KOBUNE MASAYOSHI 札幌医科大学, 医学部, 准教授 (90336389)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | BCL9 |
|---|
| Outline of Final Research Achievements |
Multiple myeloma (MM) is characterized by clonal proliferation of long-lived plasma cells within the bone marrow. Despite recent advances in its treatment, MM remains an incurable disease, underlining the need to continue exploring its molecular characteristics. We have identified that BCL9 has a pivotal role in MM pathogenesis. In this study, we found that CYBRD1, which is a iron regulating molecule, as a novel therapeutic target in MM using BCL9-Chromatin Immunoprecipitation (ChIP)-Sequence (Seq) (ChIPSeq).
|
| Free Research Field |
多発性骨髄腫
|
